Methods of modulating intracellular degradation rates of toxins

Details Methods of modulating intracellular degradation rates of toxins Methods of modulating intracellular degradation rates of toxins

2006-01-31

2006-01-31

Carlson, Karen Cochrane (Department: 1653)

Drug, bio-affecting and body treating compositions

Enzyme or coenzyme containing

Hydrolases

Reexamination Certificate

active

06991789

ABSTRACT:
The present invention provides for methods of modulating the degradation rate of a toxin in a cell, thereby modulating the half-life of the toxin. Particularly, the invention features methods of modulating the degradation rate of a toxin by modulating fusion between a lysosome and an endosome that carries the toxin in the cell.

REFERENCES:
patent: 5437291 (1995-08-01), Pasricha et al.
patent: 5670484 (1997-09-01), Binder
patent: 5714468 (1998-02-01), Binder
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5989545 (1999-11-01), Foster et al.
patent: 6063768 (2000-05-01), First
patent: 6139845 (2000-10-01), Donovan
patent: 6299893 (2001-10-01), Schwartz et al.
patent: 6306423 (2001-10-01), Donovan et al.
patent: 6312708 (2001-11-01), Donovan
patent: 6358917 (2002-03-01), Carruthers et al.
patent: 6423319 (2002-07-01), Brooks et al.
patent: 6447787 (2002-09-01), Gassner et al.
patent: 6458365 (2002-10-01), Aoki et al.
patent: 6464986 (2002-10-01), Aoki et al.
patent: 6623742 (2003-09-01), Voet
patent: 2003/0224019 (2003-12-01), O'Brien et al.
patent: 2004/0208889 (2004-10-01), Sutton et al.
patent: 101 50 415 (2003-05-01), None
patent: WO 03/0011333 (2003-02-01), None
Francis, J.W., et al. 1995. J. Biol. Chem. 270(25): 15434-15442.
O'Sullivan, G.A., et al. 1999. J. Biol. Chem. 274(52): 36897-36904.
U.S. Appl No. 10/429,069, filed May 2, 2003, Voet et al.
U.S. Appl. No. 10/630,587, filed Jul. 29, 2003, Aoki et al.
U.S. Appl. No. 10/731,973, filed Dec. 9, 2003, First.
U.S. Appl. No. 10/752,869, filed Jan. 6, 2004, First.
U.S. Appl. No. 10/423,380, filed Apr. 25, 2003, Ackerman et al.
U.S. Appl. No. 10/194,805, filed Jul. 11, 2002, Donovan.
U.S. Appl. No. 09/315,298, filed May 20, 1999, Teng et al.
Carmen Gonelle-Gispert et al., “SNAP-25a and -25b isoforms are both expressed in insulin-secreting cells and can function in insulin secretion,” Biochem. J. (1999) 339 (159-165).
Moyer et al., “Therapy With Botulinum Toxin,”Botilum Toxin Type B: Experimental And Clinical Experience, 1994, Chapter 6, pp. 71-85.
Habermann et al., “Tetanus toxin and botulinum A and C neurotoxins inhibit noradrenaline release from cultured mouse brain,”J Neurochem.Aug. 1988;51(2):522-7.
Sanchez-Prieto et al., “Botulinum Toxin A Blocks Glutamate Exocytosis From Guinea Pig Cerebral Cortical Synaptosomes,”.Eur. J. Biochem,1897, vol. 165, pp. 675-681.
Pearce, “Pharmacologic Characterization Of Botulinum Toxin For Basic Science And Medicine,”Toxicon(1997) vol. 35(9), pp. 1373-1412 at 1393.
Bigalke et al., “Botulinum A Neurotoxin Inhibits Non-Cholinergic Synaptic Transmission In Mouse Spinal Cord Neurons In Culture,”Brain Research,1985, vol. 360, pp. 318-324.
Habermann, “Inhibition By Tetanus And Botulinum A Toxin Of The Release Of [3H]Noradrenaline And [3H]GABA From Rat Brain Homogenate,”Experientia,1988, vol. 44, pp. 224-226.
Bigalke et al., “Tetanux Toxin And Botulinum A Toxin Inhibit Release And Uptake Of Various Transmitters,” 1981,Naunyn-Schmiedeberg Arch. Pharmacol,vol. 316, pp. 244-251.
Jankovic et al., “Therapy With Botulinum Toxin,”Marcel Dekker, Inc.,1994, p. 5.
Schantz et al., “Properties And Use Of Botulinum Toxin And Other Microbial Neurotoxins In Medicine,”Microbiol Rev.,1992, vol. 56, pp. 80-99.
Naumann et al., Botulinum toxin type A in the treatment of focal, axillary and palmar hyperhidrosis and other hyperhidrotic conditions,European J. Neurology,1999, vol. 6, Supp. 4, 111-115.
Bushara, “Botulinum Toxin And Rhinorrhea,”Otolaryngol Head Neck Surg.,1996, vol. 114, No. 3, p. 507.
Ragona et al., “Management of Parotid Sialocele with Botulinum Toxin,”The Laryngoscope, 1999, vol. 109, pp. 1344-1346.
Wiegand et al., “125I-labelled botulinum a neurotoxin: pharmacokinetics in cats after intramuscular injection,”Naunyn-Schmiedeberg's Arch. Pharmacol.(1976) 292:161-165.
Habermann “125I-labelled neurotoxin from clostridium Botulinum a: preparation, binding to synaptosomes and ascent to the spinal cord,”Naunyn-Schmiedeberg's Arch. Pharmacol.(1974) 281:58-56.
Murry et al., “Spasmodic dysphonia. Emotional status and botulinum toxin treatment,”Arch Otolaryngol Head Neck Surg.,Mar. 1994;120(3):310-6.
Jahanshahi et al., “Psychological functioning before and after treatment of torticollis with botulinum toxin,”J Neurol Neurosurg Psychiatry,Mar. 1992;55(3):229-31.
Bhattacharya et al., “Novel Uses Of Botulinum Toxin Type A: Two Case Reports,”Mov Disord.,2000, vol. 15, pp. 51-52.
Payne et al., “Botulinum Toxin As A Novel Treatment For Self Multilation In Lesch-Nyhan Syndrome,”Ann. Neurol.,2002, vol. 52, p. 157.
Blugerman et al., “Multiple Eccrine Hidrocystomas: A New Therapeutic Option With Botulinum Tpxom,”Dermatol. Surg.,2003, vol. 29, pp. 557-559.
Jost, “Ten Years' Experience With Botulinum Toxin In Anal Fissure,”Int. J. Colorectal Dis.,2002, vol. 17, No. 5, pp. 298-302.
Heckmann et al., “Botulinum Toxin Type A Injection In The Treatment Of Lichen Simplex: An Open Pilot Study,”J. Am. Acad. Dermatol.,2002, vol. 46, No. 4, pp. 617-619.
Aoki et al., “Mechanisms Of The Antinociceptive Effect Of Subcutaneous Botox: Inhibition Of Peripheral And Central Nociceptive Processing,”Cephalagia2003, vol. 23, No. 7, p. 649.
Li et al., “Sensory And Motor Denervation Influences Epidermal Thickness In Rat Foot Glabrous Skin,”Exp. Neurol,1997, vol. 147, pp. 452-462.
Katsambas et al., “Cutaneous Diseases Of The Foot: Unapproved Treatments,”Clin. Dermatol.,2002, pp. 689-699.
Sevim et al., “Botulinum Toxin-A Therapy For Palmar And Plantar Hyperhidrosis,”Acta Neurol. Belg.,2002, vol. 102, No. 4, pp. 167-170.
Suputtitada, “Local Botulinum Toxin Type A Injections In The Treatment Of Spastic Toes,”Am. J. Phys. Med. Rehabil.,2002, vol. 81, No. 10, pp. 770-775.
Tacks et al., “Idiopathic Toe Walking: Treatment With Botulinum Toxin A Injection,”Dev. Med. Child Neurol.,2002, vol. 44, p. 6.
Rogers et al., “Injections Of Botulinum Toxin A In Foot Dystonia,”Neurology,1993, p. 43.
Binz et al., “The Complete Sequence Of Botulinum Neurotoxin Type A And Comparison With Other Clostridial Neurotoxins,”J. Biological Chemistry,1990, vol. 265, No. 16, pp. 9153-9158.
Luzio et al., “Lysosome-endosome fusion and lysosome biogenesis,”J Cell Sci.,May 2000;113 (Pt 9):1515-24.
Fujita et al., “A dominant negative form of the AAA ATPase SKD1/VPS4 impairs membrane trafficking out of endosomal/lysosomal compartments: class E vps phenotype in mammalian cells”J Cell Sci.,Jan. 15, 2003;116(Pt 2):401-14.
Peters et al., “Control of the terminal step of intracellular membrane fusion by protein phosphatase 1,”Science,Aug. 13, 1999;285(5430):1084-7.
Mousavi et al., “Phosphoinositide 3-kinase regulates maturation of lysosomes in rat hepatocytes,” Biochem J. Jun. 15, 2003;372(Pt 3):861-9.
Zucker et al., “Rapid trafficking of membrane type 1-matrix metalloproteinase to the cell surface regulates progelatinase A activation”Lab Invest.,2002, vol. 82, No. 12, pp. 1673-1684.
Ramm et al., “Pathways of intracellular trafficking and release of ferritin by the liver in vivo: the effect of chloroquine and cytochalasin D,” Hepatology. Feb. 19, 1994;(2):504-13.
Al-Jaufy et al., “Purification and characterization of a shiga toxin a subunit-CD4 fusion protein cytotoxic to human immunodeficiency virus-infected cells,”Infection and Immunity(1995) 63(8):3073-3078.
Ohashi et al., “An arrested late endosome-lysosome intermediate aggregate observed in a Chinese hamster ovary cell mutant isolated by novel three-step screening,”J. of Cell Science(1999) 112:1125-1138.
Huete-Pérez et al., “Protease trafficking in two primitive eukaryotes is mediated by a prodomain protein moti

Affiliated with

Also associated with

Rating

Methods of modulating intracellular degradation rates of toxins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Methods of modulating intracellular degradation rates of toxins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of modulating intracellular degradation rates of toxins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3565937